Given interim look, I'd be surprised if final result isn't positive. But hard to say how much of a boost agix will get given the noise from cleveland clinic and elsewhere. Won't necessarily ebb with full data.
For me, interim was somewhat confounding given pbo+statin arm also showed regression. Will be interesting to see if that holds with complete data.
Market Data 
Markets 
AI
